Evogene
Biotechnology company developing novel products for life science markets through the use of a unique CPB platform.
- dt and ls
- biotechnology
- horizon europe
- sustainable development goals
- biotech and pharma
- climate tech
- core ai
- ai applications
- dietary supplements
- superfood
- genetics and genomics
- predictive analytics
- drug development
- genome engineering
- ai drug discovery
- techbio
- digital pharma
- organic
- techbio drug discovery
- biofuel
- crop protection
- crop
- gmo
- biopesticides
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $5.5m | Private Placement non VC |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (11 %) | 80 % | 237 % | 51 % | (24 %) | 113 % | 44 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2880 %) | (1424 %) | (404 %) | (226 %) | (223 %) | (88 %) | (51 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2988 %) | (1590 %) | (423 %) | (194 %) | (259 %) | (118 %) | (82 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2566 % | 1241 % | 368 % | 196 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Evogene Ltd. operates as a computational biology company, focusing on the development of products for life-science-based industries. Established in 1999 as a spin-off from Compugen, the company leverages its proprietary discovery and development platforms to enhance the performance of products in sectors such as human health, agriculture, and industrial applications. The company was founded by Dr. Hagai Karchi and Ofer Haviv. Mr. Haviv, who has served as President and CEO since 2007, brings a background in economics and business administration from the Recanati Business Administration School of Tel Aviv University. Dr. Karchi, a key figure in the company's scientific foundation, has a Ph.D. in genetics and plant breeding from the Weizmann Institute of Science.
Evogene's business strategy revolves around a hub-and-spoke model, establishing and supporting subsidiary companies that utilize its foundational technology for specific market needs. The core of its operation is the ChemPass AI engine, which aids in the discovery of novel small molecules. Another key technology is the GeneRator AI engine, designed to identify genes and proteins with the potential to improve desired traits. These platforms serve as the technological backbone for its subsidiaries.
The company's revenue is generated through various streams, including research and development payments, milestone achievements, and future royalties from the commercialization of products developed by its subsidiaries and partners. Evogene's main subsidiaries include Biomica, which focuses on microbiome-based therapeutics for immuno-oncology; Lavie Bio, dedicated to developing ag-biologicals for crop protection and enhancement; AgPlenus, which designs sustainable crop protection solutions; and Casterra, aimed at providing an integrated solution for industrial-scale castor bean cultivation. This diversified structure allows Evogene to target multiple high-value markets simultaneously, from biopharmaceuticals to sustainable agriculture.
Keywords: computational biology, life sciences, ag-tech, drug discovery, AI platform, microbiome, crop protection, biopharmaceuticals, sustainable agriculture, castor cultivation
